Draft:ESCAT

Submission declined on 8 March 2026 by WeirdNAnnoyed (talk). This draft provides insufficient context for those unfamiliar with the subject. Please see the guide to writing better articles for how to improve your writing. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by WeirdNAnnoyed 5 months ago. Last edited by Citation bot 31 days ago. Reviewer: Inform author. Resubmit Please note that if the issues are not fixed, the draft will be declined again.

• Comment: I think this subject is notable, but the draft article needs work. It is far too detailed and technical for the average user; a reader who needs this level of detail will find a review article or technical report. Please simplify the text and consider cutting the number of examples. Based on the formatting I also suspect an LLM was used in preparation of the article, which raises sourcing issues, but all the sources I checked were appropriate so this is a much lesser concern. WeirdNAnnoyed (talk) 13:15, 8 March 2026 (UTC)

ESCAT (ESMO Scale for Clinical Actionability of Molecular Targets) is a systematic framework for ranking molecular targets for precision cancer therapy based on the strength of clinical evidence supporting their use. The scale was introduced in 2018 through a collaborative initiative led by the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group. The scale was designed to support clinical decision-making in precision oncology by providing a standardized method for evaluating the clinical actionability of genomic alterations identified through molecular testing.^[1]

ESCAT provides a structured hierarchy for interpreting genomic alterations identified through next-generation sequencing (NGS). By organizing alterations into evidence-based tiers, the framework helps clinicians determine which molecular targets should be prioritized for therapeutic intervention. The highest tiers represent genomic alterations with well-established clinical benefit, while the lowest tiers include alterations with limited or no evidence of clinical utility. The scale was designed to standardize interpretation across institutions, healthcare systems, and geographic regions. By creating a shared language for clinical actionability, ESCAT supports consistent decision-making in precision oncology.^[2]

Clinical application of ESCAT has demonstrated value across multiple tumour types, including breast cancer and cholangiocarcinoma. Studies have shown that patient outcomes tend to improve when treatments are selected based on alterations ranked in the higher ESCAT tiers.^[3] In addition, the framework has informed recommendations from ESMO regarding the appropriate conduct and reporting of NGS testing, particularly in identifying cancer types most likely to benefit from comprehensive genomic profiling.^[4]

Advances in cancer biology and high-throughput sequencing technologies have transformed oncology research and clinical practice. The growing accessibility of tumour genomic profiling has facilitated the emergence of Precision Cancer Medicine (PCM), in which treatments are selected based on specific molecular alterations within a tumour. As genomic testing became more widely adopted, clinicians began encountering increasingly complex sequencing reports. Many patients now undergo multi-gene panel testing to identify potential therapeutic targets. However, not all detected alterations carry the same level of clinical significance. Some are supported by robust evidence from clinical trials, while others are based on early-phase studies, pre-clinical findings, or hypothetical gene–drug associations.

Sequencing reports often lack standardized prioritization, and the absence of harmonized classification systems can lead to inconsistent interpretation. In some cases, patients may receive therapies targeting unproven targets, while stronger evidence-based alterations may not be clearly distinguished.^[5]

ESCAT was developed to support oncologists in prioritizing genomic findings from broad sequencing panels and to establish a common terminology applicable across clinical care, research, and drug development. It also aimed to improve communication among key stakeholders in precision oncology, including molecular diagnostic laboratories, treating physicians, researchers, and patients.

Dr. Fabrice André, Chair of the ESMO Translational Research and Precision Medicine Working Group at the time of ESCAT’s development, noted that the scale was intended to help clinicians interpret the growing volume of tumour genomic information and distinguish alterations relevant for targeted treatment or clinical trial enrolment from those that lack clinical significance.^[6]

ESCAT was developed through an international collaborative effort involving scientists and clinicians, primarily from Europe. The working group first defined the core principles underlying the classification system, with emphasis placed on clinical evidence of therapeutic benefit.^[7]

The primary criterion for categorization is the level of clinical evidence supporting the use of a drug to target a specific molecular alteration. The framework focuses on demonstrated clinical actionability rather than biological plausibility alone. Pathogenicity or predicted functional impact of a mutation is not sufficient for classification unless supported by clinical data showing therapeutic benefit.^[7]

The classification comprises multiple tiers, reflecting decreasing levels of clinical evidence. Additional subcategories clarify specific clinical scenarios, such as evidence derived from randomized trials, basket trials, or tumour types different from the one under consideration.

The ESCAT framework is defined by several core characteristics designed to bridge the gap between complex genomic data and clinical decision-making.

ESCAT organizes genomic alterations into a descending hierarchy based on the strength of the supporting data. (See Classification)

ESCAT prioritizes ranking based on clinical actionability, rather than predicted functional impact or biological pathogenicity. For example, a mutation that is biologically "driver-like" but lacks a proven drug match remains in the lower tiers (Tier IV). The primary metric for a high ranking is the demonstrated improvement in patient survival or objective response rates within clinical trials.^[1]

ESCAT distinguishes between evidence that is specific to a particular cancer and evidence that applies across multiple malignancies:

• Tumour-Specific (Tier I-A/B): Rankings are often tied to a specific histology, cancer, or tumour type. An alteration might be Tier I in one tumour type but Tier III in another where the drug has not been validated. (See Tier I-A and Tier I-B)

• Tumour-Agnostic (Tier I-C): Recognizes basket trial evidence where certain alterations predict drug response regardless of where the tumour originated in the body.^[4] (See Tier I-C).

Alteration-drug match is associated with improved outcome in clinical trials.

Prospective, randomized clinical trials show the alteration-drug match in a specific tumour type results in a clinically meaningful improvement of a survival end point.

Examples:

• ERBB2 amplification in breast tumour → trastuzumab (Herceptin)^[8][9][10]
• EGFR activating mutation in non-small-cell lung cancer (NSCLC) → osimertinib (Tagrisso)^[11][12]

Prospective, non-randomized clinical trials show that the alteration-drug match in a specific tumour type, results in clinically meaningful benefit as defined by ESMO MCBS 1.1.^[13]

Examples:

• ROS-rearrangement in NSCLC → crizotinib (Xalkori)^[14], ceritinib (Zykadia)^[15][16]

Clinical trials across tumour types or basket clinical trials show clinical benefit associated with the alteration-drug match, with similar benefit observed across tumour types.

Examples:

• NTRK fusion in various tumours → larotrectinib (Vitrakvi)^[17]
• PD-L1 overexpression in various tumours → pembrolizumab (Keytruda)^[18]

Alteration-drug match is associated with antitumour activity, but magnitude of benefit is unknown.

Retrospective studies show patients with the specific alteration in a specific tumour type experience clinically meaningful benefit with matched drug compared with alteration-negative patients.

Examples:

• PTEN and the PI3-Kinase pathway in various cancer → ipatasertib (GDC-0068)^[19]

Prospective clinical trial(s) show the alteration-drug match in a specific tumour type results in increased responsiveness when treated with a matched drug, however, no data currently available on survival end points.

Examples:

• AKT1 activating mutations in E17K → AZD5363^[20][21]

Alteration-drug match suspected to improve outcome based on clinical trial data in other tumour type(s) or with similar molecular alteration

Clinical benefit demonstrated in patients with the specific alteration (as tiers I and II above) but in a different tumour type. Limited/absence of clinical evidence available for the patient-specific cancer type or broadly across cancer types.

Examples:

• Limited activity of vemurafenib (Zelboraf) in BRAF-mutated colorectal cancers^[22]
  • BRAF V600E mutation in metastatic melanomas → vemurafenib (Zelboraf)^[23]

An alteration that has a similar predicted functional impact as an already studied tier I abnormality in the same gene or pathway, but does not have associated supportive clinical data.

Examples:

• BRCA1/2 and PALB2 loss-of-function mutations in prostate and pancreatic cancers^{[24][25][26][27]}
  • BRCA1 or BRCA2 loss-of-function mutations in breast and ovarian cancers → niraparib (Zejula)^[28], olaparib (Lynparza)^[29], PARP inhibitors

Pre-clinical evidence of actionability.

Evidence that the alteration or a functionally similar alteration influences drug sensitivity in preclinical in vitro or in vivo models.

Actionability predicted in silico.

Alteration-drug match is associated with objective response, but without clinically meaningful benefit.

Examples:

• PIK3CA activating mutation in estrogen receptor-positive, HER2-negative breast cancers
  • Clinical trials demonstrated that targeting PI3K leads to objective responses in patients with activating PIK3CA mutations but did not impact outcome.^[30]

Lack of evidence for actionability.

Molecular tumour boards frequently employ the ESCAT framework to standardize interpretation of genomic findings and treatment recommendations. At the Medical University of Vienna, clinicians have used this scale to justify off-label therapy choices during patient case reviews.^[31] By categorizing alterations into specific tiers, these boards can distinguish between variants with proven clinical utility and those that remain hypothetical.^[31] Retrospective analyses at the Institut Curie have further validated this approach by showing that patients with higher-tier alterations, specifically Tiers I and II, experienced better survival outcomes when matched with corresponding therapies compared to those with lower-tier findings.^[32] The structured classification ESCAT provides helps prevent the overinterpretation of genomic data and ensure that patients receive the most effective available treatments.^[31]

The ESCAT system is also used to create cancer-specific rankings that help physicians prioritize recurrent molecular alterations within a particular tumour type.^[33] For example, in the context of head and neck squamous-cell carcinoma, researchers analyzed 33 genes to establish a hierarchy of actionability, ranking HRAS mutations as Tier I-B and NTRK fusions as Tier I-C.^[33] Similarly, the scale has been applied to early-stage disease to understand the landscape of actionable targets. There has been a descriptive analysis of a large prospective cohort of early-stage ovarian cancer patients, using ESCAT to map out which mutations could potentially be targeted by existing drugs.^[34]

Large-scale precision medicine programs have adopted ESCAT as a metric to evaluate their overall success and monitor the identification of actionable targets over time.^[35] The Vall d’Hebron Institute of Oncology reviewed a decade of genomic data and documented a substantial increase in the proportion of patients harbouring actionable alterations as testing technologies matured.^[35] Furthermore, the Copenhagen Prospective Personalized Oncology study utilized the framework within a phase I trial unit to confirm that ESCAT tiers accurately predict treatment response.^[3] Their study, which included over 2,000 patients, showed that using the scale to guide therapy selection resulted in higher objective response rates and improved progression-free survival in patients with advanced solid tumours.^[3]

At the systemic level, the ESCAT framework has informed international public health guidelines on the routine implementation of next-generation sequencing. The ESMO Precision Medicine Working Group used these evidence tiers to determine when the clinical benefit of multi-gene sequencing outweighs the financial and logistical costs for common cancers.^[4]

The ESCAT classification system has several limitations. A major drawback is that ESCAT does not provide clear guidance for treatment prioritization when a patient has multiple coexisting molecular alterations mapped to the same or different tiers.^[33] The framework also lacks specific instructions for integrating molecular alterations that indicate treatment resistance into the clinical decision-making process.^[33] The inherent heterogeneity of tumours and the continuous clonal evolution of cancer under therapeutic pressure complicate the static interpretation of the ESCAT tiers, as sub-clonal driver events can be difficult to validate for clinical actionability.^[33][1] Finally, implementing ESCAT in routine clinical practice presents logistical challenges, as establishing the necessary sequencing platforms and bioinformatic tools for variant interpretation requires substantial external validation before clinical application.^[1]

As the field of precision medicine evolves, there are several areas for the expansion and refinement of the ESCAT framework. One important ongoing effort is the continuous updating of ESCAT to keep pace with advancements in therapeutic research and clinical trial data, ensuring that rankings reflect the most current therapeutic standards. Future iterations of ESCAT could also be improved by the integration of markers of treatment resistance alongside actionability, providing clinicians with a more holistic view that could improve therapy recommendations.^[33] There is also a need to standardize the interpretation and prioritization of co-occurring alterations. Patients frequently harbour multiple mutations, mapping to the same or different tiers, that may interact or require combination therapies not currently addressed by ESCAT.^[33] The integration of ESCAT into automated bioinformatic pipelines would also be a valuable next step, allowing molecular tumour boards to generate evidence-based reports and recommendations more efficiently. Finally, the harmonization of ESCAT with other major classification systems, such as those created by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP), would help create a unified global language and understanding in precision oncology.^[31]